The Issue with Reissue: PTE Edition
FDA Law Blog: Biosimilars
MARCH 18, 2025
Specifically, the Court focused on the purpose: to compensate pharmaceutical companies for the effective truncation of their patent terms while waiting for regulatory approval of new drug applications. The question is important because the result of that determination could drastically reduce the amount of patent term to be restored.
Let's personalize your content